Pharmacological profile of 9,11-dehydrocortexolone 17α-butyrate (CB-03-04), a new androgen antagonist with antigonadotropic activity

Arzneimittel-Forschung/Drug Research

Volumn 55, Issue 10, 2005, Pages 581-587

  Celasco, Giuseppe ^a   Moro, Luigi ^a   Bozzella, Roberta ^a   Ferraboschi, Patrizia ^b   Bartorelli, Luisa ^a   Di Marco, Roberto ^c   Quattrocchi, Cinzia ^c   Nicoletti, Ferdinando ^c  

^a Cosmo SpA ^*  (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

9,11 Dehydrocortexolone 17 butyrate, hamster, pharmacological profile, rat; Antiandrogens; CB 03 04; Cyproterone acetate; Finasteride; Flutamide; Gonadotropin inhibitors

Indexed keywords

9,11 DEHYDROCORTEXOLONE 17ALPHA BUTYRATE; ANABOLIC AGENT; ANDROSTANOLONE; ANTIANDROGEN; CB 03 04; CORTICOSTERONE; CORTODOXONE; CYPROTERONE ACETATE; FINASTERIDE; FLUTAMIDE; GLUCOCORTICOID; GONADOTROPIN; GONADOTROPIN ANTAGONIST; PROGESTERONE; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOASSAY; CASTRATION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DRUG MECHANISM; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; GONADOTROPIN RELEASE; LEVATOR ANI MUSCLE; MALE; NONHUMAN; PARABIOSIS; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; RAT; SEMINAL VESICLE; STRUCTURE ACTIVITY RELATION; SYRIAN HAMSTER;

EID: 27544489044     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296908     Document Type: Article

References (20)

1. Huggins, C., Hodges, C. V., Studies on prostatic cancer. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1, 293 (1941)
2. Huggins, C., Stevens, R. E., Hodges, C. V., Studies on prostatic cancer II. The effect of castration on advanced carcinoma of the prostate gland. Arch. Surg. 43, 209 (1941)
3. Motta, M., in: The Medical Management of Prostate Cancer, L. Denis (ed.), pp. 19-35. Springer-Verlag, Berlin (1988)
4. Neumann, F., in: Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action, B. J. A. Furr, A. E. Wakeling (eds.), pp. 132-159. Bailliere Tindal, London (1987)
5. Migliari, R., Muscas, G., Murru, M. et al., Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy. Arch. Ital. Urol. Androl. 71, 293 (1999)
6. Neumann, F., Töpert, M., Pharmacology of antiandrogens. J. Steroid Biochem. 25, 885 (1986)
7. Voigt, W., Hsia, S. L., The anti-androgenic action of 4-androsten-3-one-17β-carboxylic acid and its methyl ester on hamster flank organ. Endocrinology 92, 1216 (1973)
8. Dorfman, R. I., in: Methods in Hormone Research, R.I. Dorfman (ed.), vol. 2, pp. 315-323. Academic Press, New York-London (1962)
9. Shipley, E. G., in: Methods in Hormone Research, R. I. Dorfman (ed.), vol. 2, pp. 179-274. Academic Press, New York-London (1962)
10. Mattingly, D., A simple fluorimetric method for the estimation of free 11-hydroxycorticoids in human plasma. J. Clin. Pathol. 15, 374 (1962)
11. Singh, S. M., Gautier, S., Labrie, F., Androgen receptor antagonists (antiandrogens): structure-activity relationship. Curr. Med. Chem. 7, 211 (2000)
12. Glenn, E. M., Richardson, S. L., Bowman, B. J., Biological activity of 6α-hydroxyprogesterone acetate and compound S. Metabolism 8, 265 (1959)
13. Snyder, B. W., Winneker, R. C., Batzold, F. H., Endocrine profile of WIN 49596 in the rat: A novel androgen receptor antagonist. J. Steroid Biochem. 33, 127 (1989)
14. de Voogt, H. J., The position of cyproterone acetate (CPA), a steroid anti-androgen, in the treatment of prostate cancer. Prostate Suppl. 4, 91 (1992)
15. Reid, P., Kantoff, P., Oh, W., Antiandrogens in prostate cancer. Invest. New Drugs 17, 271 (1999)
16. Poyet, P., Labrie, F., Comparison of the anti-androgenic/ androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol. Cell. Endocrinol. 42, 283 (1985)
17. Girard, J., Baumann, J. B., Buhler, U. et al., Cyproterone acetate and ACTH adrenal function. J. Clin. Endocrinol. Metab. 47, 581 (1978)
18. Neri R. O., Monahan M. D., Meyer J. G. et al., Biological studies on an anti-androgen (SH 714). Eur. J. Pharmacol. 1, 438 (1967)
19. Furr, B. J., Tucker, H., The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology 47 (Suppl. 11A), 13 (1996)
20. Smith, M. R., Osteoporosis during androgen deprivation therapy for prostate cancer. Urology 60 (Suppl. 1), 79 (2002)